Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) insider Nicole S. White sold 1,255 shares of the firm's stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $12.71, for a total transaction of $15,951.05. Following the sale, the insider now directly owns 13,025 shares of the company's stock, valued at $165,547.75. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Assembly Biosciences Trading Up 6.4 %
ASMB stock opened at $13.27 on Thursday. The stock's fifty day moving average is $13.17 and its two-hundred day moving average is $11.15. Assembly Biosciences, Inc. has a 1 year low of $7.69 and a 1 year high of $20.04.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 54,464 shares of the biopharmaceutical company's stock, valued at approximately $45,000. Marquette Asset Management LLC owned approximately 0.08% of Assembly Biosciences as of its most recent SEC filing. 19.92% of the stock is owned by institutional investors.
Analyst Ratings Changes
Look Who Fired the World’s Richest Man
From Banyan Hill Publishing | Ad
This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S.
And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.
Get the full story here.
A number of brokerages have weighed in on ASMB. HC Wainwright restated a "neutral" rating on shares of Assembly Biosciences in a research note on Monday, April 1st. StockNews.com upgraded Assembly Biosciences from a "sell" rating to a "hold" rating in a research report on Friday, April 5th.
View Our Latest Stock Analysis on Assembly Biosciences
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
